CAMBRIDGE, Mass., Feb. 10, 2021 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the appointment of Lisa
Kelly-Croswell to its board of directors.
"We are delighted to welcome Lisa to our Board," said Aoife
Brennan, M.B, Ch.B., Synlogic's President and Chief
Executive Officer. "Lisa is an exceptional leader with over 25
years of experience across the healthcare spectrum. Her expertise
in rapid growth business environments and building high impact
teams to drive innovation will be hugely valuable to Synlogic. We
are looking forward to learning from Lisa's experience in
healthcare delivery and organizational effectiveness as we drive
towards making a meaningful impact for patients."
Lisa Kelly-Croswell is a global
Human Resources executive with over 30 years of experience in
assignments commonly involving rapid business growth, performance
turnarounds and innovation. Lisa currently serves as Senior Vice
President and Chief Human Resources Officer for Boston Medical
Center Health System (BMCHS)—an academic medical center including a
health plan as well as biomedical and clinical research portfolios.
Prior to BMCHS, Ms. Kelly-Croswell was Senior Vice President, HR
and Corporate Services at Vertex Pharmaceuticals, where for seven
years she was part of the executive team evolving the company from
an early stage biotech, to a fully commercialized pharmaceutical
company. Prior to Vertex, she also served as Vice President, HR for
Nitromed, a biotech with an approved personalized medicine.
Previously, Ms. Kelly-Croswell served as SVP, HR for Healthcare
and Service Operations at CIGNA. She also held multiple leadership
roles at the Monsanto Company in global Finance, R&D, and as an
expatriate based in Singapore. She
began her career in a series of progressive HR positions at
Frito-Lay, Inc. with a deeper focus in manufacturing, and received
a B.S., Finance and M.A., Labor and Industrial Relations from the
University of Illinois at
Urbana-Champaign. She is a current and past Board Member for
multiple non-profit organizations.
"Great biotech companies begin and end with people," said Ms.
Kelly-Croswell. "The patients they serve, and the people that make
it all happen. I am thrilled to be joining Synlogic at such a
growth stage in the company's history. With three programs moving
through the clinic and a talented team driving towards a data rich
2021, I welcome the opportunity to contribute to the continued
success of both the company and the patients they hope to
benefit."
Learn more about Synlogic's programs and pipeline by visiting
https://www.synlogictx.com/.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synlogic-appoints-lisa-kelly-croswell-to-its-board-of-directors-301225674.html
SOURCE Synlogic, Inc.